Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Hamasy

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
Scandinavian Journal of Immunology|May 16, 2013
Inhibitors of BTK and ITK: state of the new drugs for cancer, autoimmunity and inflammatory diseasesL Vargas, A Hamasy, B F Nore, et al.
Scandinavian Journal of Immunology|June 26, 2015
Targets for Ibrutinib Beyond B Cell MalignanciesA Berglöf, A Hamasy, S Meinke, et al.
Leukemia|June 11, 2016
Substitution scanning identifies a novel, catalytically active ibrutinib-resistant BTK cysteine 481 to threonine (C481T) variantA Hamasy, Q Wang, K E M Blomberg, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
Scandinavian Journal of Immunology|May 16, 2013
Inhibitors of BTK and ITK: state of the new drugs for cancer, autoimmunity and inflammatory diseasesL Vargas, A Hamasy, B F Nore, et al.
Scandinavian Journal of Immunology|June 26, 2015
Targets for Ibrutinib Beyond B Cell MalignanciesA Berglöf, A Hamasy, S Meinke, et al.
Leukemia|June 11, 2016
Substitution scanning identifies a novel, catalytically active ibrutinib-resistant BTK cysteine 481 to threonine (C481T) variantA Hamasy, Q Wang, K E M Blomberg, et al.
Pageof 1